Trinity Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2002
Revenue	56.83	62.52	81.15	101.98	90.44	Upgrade
Revenue Growth (YoY)	-9.10%	-22.96%	-20.43%	12.77%	-6.80%	Upgrade
Cost of Revenue	37.38	45.25	47.7	53.4	52.32	Upgrade
Gross Profit	19.45	17.27	33.45	48.58	38.12	Upgrade
Selling, General & Admin	31.15	26.98	22.5	27.5	32.7	Upgrade
Research & Development	4.38	4.14	4.5	5.08	5.33	Upgrade
Other Operating Expenses	10.96	5.5	2.52	15.92	24.2	Upgrade
Operating Expenses	46.5	36.62	29.52	48.5	62.23	Upgrade
Operating Income	-27.05	-19.35	3.94	0.08	-24.11	Upgrade
Interest Expense / Income	11.05	24.73	7.09	6.75	6.58	Upgrade
Other Expense / Income	-14.02	-2.88	-3.95	0.34	-0.77	Upgrade
Pretax Income	-24.08	-41.2	0.8	-7.01	-29.92	Upgrade
Income Tax	-0.06	-0.19	-0.07	-0.62	-1.01	Upgrade
Net Income	-24.02	-41.01	0.88	-6.39	-28.91	Upgrade
Shares Outstanding (Basic)	152	84	84	84	96	Upgrade
Shares Change	82.32%	-	-	-13.06%	-	Upgrade
EPS (Basic)	-3.20	-6.00	0.20	-1.60	-7.00	Upgrade
EPS (Diluted)	-3.20	-6.00	0.20	-1.60	-7.00	Upgrade
Free Cash Flow	-14.57	-6.89	2.94	14.47	-6.44	Upgrade
Free Cash Flow Per Share	-1.91	-1.65	0.70	3.46	-1.34	Upgrade
Gross Margin	34.22%	27.62%	41.23%	47.64%	42.15%	Upgrade
Operating Margin	-47.59%	-30.95%	4.85%	0.08%	-26.66%	Upgrade
Profit Margin	-42.26%	-65.59%	1.08%	-6.26%	-31.97%	Upgrade
Free Cash Flow Margin	-25.64%	-11.01%	3.62%	14.19%	-7.12%	Upgrade
Effective Tax Rate	-	-	-9.24%	-	-	Upgrade
EBITDA	-11.25	-14.14	10.63	2.82	-18.44	Upgrade
EBITDA Margin	-19.79%	-22.61%	13.10%	2.77%	-20.39%	Upgrade
Depreciation & Amortization	1.78	2.33	2.74	3.08	4.89	Upgrade
EBIT	-13.02	-16.47	7.89	-0.26	-23.34	Upgrade
EBIT Margin	-22.92%	-26.34%	9.72%	-0.25%	-25.81%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).